---
layout: post
title: "艾德生物：公司产品进入日本医保"
date: 2022-01-07 16:29:05 +0800
categories: zhengquanshibao
tags: 证券时报新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.300685" data-code="300685|0|2" data-code2="300685|0|80|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.300685&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 300685_0" data-code="K 300685|0|2" data-code2="K 300685|0|80|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>艾德生物(300685)1月7日晚间公告，公司基于PCR技术平台自主研发的肺癌多基因联合检测产品“AmoyDxPanlungcancerPCRpanel”(即PCR-11基因)于近日被纳入日本医保。该产品用于检测多个肺癌核心驱动基因。<br /></p><p class="em_media">（文章来源：证券时报）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202201072240287345>

[返回证券时报新闻](//finews.withounder.com/category/zhengquanshibao.html)｜[返回首页](//finews.withounder.com/)